{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:25Z","timestamp":1791357265595,"version":"4.3.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:00:00Z","timestamp":1536192000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s40266-018-0579-6","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T21:36:56Z","timestamp":1536183416000},"page":"887-895","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["A Review of the Pharmacological and Clinical Profile of Newer Atypical Antipsychotics as Treatments for Bipolar Disorder: Considerations for Use in Older Patients"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0423-4598","authenticated-orcid":false,"given":"Akshya","family":"Vasudev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rickinder","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"Sandieson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent P.","family":"Forester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,6]]},"reference":[{"key":"579_CR1","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/9780470661277.ch38","volume-title":"Bipolar disorder: clinical and neurobiological foundations","author":"M Sajatovic","year":"2010","unstructured":"Sajatovic M, Kessing LV. Bipolar disorder in the elderly. In: Yatham LN, Maj M, editors. Bipolar disorder: clinical and neurobiological foundations. Hoboken: Wiley; 2010. p. 488\u201398."},{"issue":"7","key":"579_CR2","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/bdi.12331","volume":"17","author":"M Sajatovic","year":"2015","unstructured":"Sajatovic M, Strejilevich SA, Gildengers AG, Dols A, Al Jurdi RK, Forester BP, et al. A report on older-age bipolar disorder from the International Society for Bipolar Disorders Task Force. Bipolar Disord. 2015;17(7):689\u2013704.","journal-title":"Bipolar Disord"},{"issue":"6","key":"579_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/0269881116636545","volume":"30","author":"G Goodwin","year":"2016","unstructured":"Goodwin G, Haddad P, Ferrier I, Aronson J, Barnes T, Cipriani A, et al. Evidence-based guidelines for treating bipolar disorder revised third edition: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30(6):495\u2013553.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"579_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","volume":"20","author":"LN Yatham","year":"2018","unstructured":"Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97\u2013170.","journal-title":"Bipolar Disord"},{"issue":"2","key":"579_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/(SICI)1520-6394(1998)7:2<76::AID-DA5>3.0.CO;2-3","volume":"7","author":"JC Hays","year":"1998","unstructured":"Hays JC, Krishnan KRR, George LK, Blazer DG. Age of first onset of bipolar disorder: Demographic, family history, and psychosocial correlates. Depress Anxiety. 1998;7(2):76\u201382.","journal-title":"Depress Anxiety"},{"issue":"10","key":"579_CR6","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1161\/CIR.0000000000000229","volume":"132","author":"BI Goldstein","year":"2015","unstructured":"Goldstein BI, Carnethon MR, Matthews KA, McIntyre RS, Miller GE, Raghuveer G, et al. major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2015;132(10):965\u201386.","journal-title":"Circulation"},{"issue":"8","key":"579_CR7","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/gps.1730","volume":"22","author":"H Subramaniam","year":"2007","unstructured":"Subramaniam H, Dennis MS, Byrne EJ. The role of vascular risk factors in late onset bipolar disorder. Int J Geriatr Psychiatry. 2007;22(8):733\u20137.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"11","key":"579_CR8","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s00127-012-0478-9","volume":"47","author":"A Kodesh","year":"2012","unstructured":"Kodesh A, Goldshtein I, Gelkopf M, Goren I, Chodick G, Shalev V. Epidemiology and comorbidity of severe mental illnesses in the community: Findings from a computerized mental health registry in a large Israeli health organization. Soc Psychiatry Psychiatr Epidemiol. 2012;47(11):1775\u201382.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"579_CR9","first-page":"1229","volume":"45","author":"KI Shulman","year":"1999","unstructured":"Shulman KI, Herrmann N. Bipolar disorder in old age. Can Fam Physician. 1999;45:1229\u201337.","journal-title":"Can Fam Physician"},{"issue":"2","key":"579_CR10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1176\/ps.2009.60.2.147","volume":"60","author":"B Roshanaei-Moghaddam","year":"2009","unstructured":"Roshanaei-Moghaddam B, Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr Serv. 2009;60(2):147\u201356.","journal-title":"Psychiatr Serv."},{"key":"579_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.maturitas.2010.02.013","volume":"66","author":"A Vasudev","year":"2010","unstructured":"Vasudev A, Thomas A. \u201cBipolar disorder\u201d in the elderly: what\u2019s in a name? Maturitas. 2010;66:231\u20135.","journal-title":"Maturitas"},{"issue":"3","key":"579_CR12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.amjopharm.2007.10.001","volume":"5","author":"MW Bowie","year":"2007","unstructured":"Bowie MW, Slattum PW. Pharmacodynamics in older adults: a review. Am J Geriatr Pharmacother. 2007;5(3):263\u2013303.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"1","key":"579_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2004","unstructured":"Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6\u201314.","journal-title":"Br J Clin Pharmacol"},{"key":"579_CR14","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.cger.2013.07.002","volume":"29","author":"CN Harada","year":"2013","unstructured":"Harada CN, Natelson Love MC, Triebel KL. Normal cognitive aging. Clin Geriatr Med. 2013;29:737\u201352.","journal-title":"Clin Geriatr Med"},{"key":"579_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.psc.2011.02.007","volume":"34","author":"M Sajatovic","year":"2011","unstructured":"Sajatovic M, Chen P. Geriatric bipolar disorder. Psychiatr Clin N Am. 2011;34:319\u201333.","journal-title":"Psychiatr Clin N Am"},{"issue":"11","key":"579_CR16","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1097\/JGP.0b013e318187135f","volume":"16","author":"RK Al Jurdi","year":"2008","unstructured":"Al Jurdi RK, Marangell LB, Petersen NJ, Martinez M, Gyulai L, Sajatovic M. Prescription Patterns of psychotropic medication in the elderly compared to younger particioants who achieved a \u201crecovered\u201d status in the Systematic Treatment Rnhancement Program for Bipolar Disorder (STEP-BD). Am J Geriatr Psychiatry. 2008;16(11):922\u201333.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"579_CR17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/00019442-200407000-00002","volume":"12","author":"RC Young","year":"2004","unstructured":"Young RC, Gyulai L, Mulsant BH, Flint A, Beyer JL, Shulman KI, et al. Pharmacotherapy of bipolar disorder in old age: review and recommendations. Am J Geriatr Psychiatry. 2004;12(4):342\u201357.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"579_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/00019442-200504000-00008","volume":"13","author":"AG Gildengers","year":"2005","unstructured":"Gildengers AG, Mulsant BH, Begley AE, McShea M, Stack JA, Miller MD, et al. A pilot study of standardized treatment in geriatric bipolar disorder. Am J Geriatr Psychiatry. 2005;13(4):319\u201323.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"11","key":"579_CR19","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1176\/appi.ajp.2017.15050657","volume":"174","author":"RC Young","year":"2017","unstructured":"Young RC, Mulsant BH, Sajatovic M, Gildengers AG, Gyulai L, Al Jurdi RK, et al. GERI-bd: A randomized double-blind controlled trial of lithium and divalproex in the treatment of mania in older patients with bipolar disorder. Am J Psychiatry. 2017;174(11):1086\u201393.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"579_CR20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1124\/pr.111.005512","volume":"65","author":"C-T Chiu","year":"2013","unstructured":"Chiu C-T, Wang Z, Hunsberger JG, Chuang D-M. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev. 2013;65(1):105\u201342.","journal-title":"Pharmacol Rev"},{"key":"579_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/00043426-200001000-00012","volume":"22","author":"S Acharya","year":"2000","unstructured":"Acharya S, Bussel J. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol. 2000;22:62\u20135.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6","key":"579_CR22","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1185\/03007995.2012.694362","volume":"28","author":"C Lewis","year":"2012","unstructured":"Lewis C, Deshpande A, Tesar GE, Dale R. Valproate-induced hyperammonemic encephalopathy: a brief review. Curr Med Res Opin. 2012;28(6):1039\u201342.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"579_CR23","first-page":"4","volume":"159","author":"Anonymous","year":"2002","unstructured":"Anonymous. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(4):4\u201350.","journal-title":"Am J Psychiatry"},{"key":"579_CR24","unstructured":"Ruscin JM, Linnebur SA. Pharmacokinetics in the Elderly\u2014Geriatrics\u2014Merck Manuals Professional Edition. Merck Manual online. 2014. \n                    http:\/\/www.merckmanuals.com\/professional\/geriatrics\/drug-therapy-in-the-elderly\/pharmacokinetics-in-the-elderly#v1132432\n                    \n                  ."},{"issue":"3","key":"579_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4103\/0019-5545.37325","volume":"49","author":"E Mohandas","year":"2007","unstructured":"Mohandas E, Rajmohan V. Lithium use in special populations. Indian J Psychiatry. 2007;49(3):211\u20138.","journal-title":"Indian J Psychiatry"},{"issue":"1","key":"579_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2003","unstructured":"Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2003;57(1):6\u201314.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"579_CR27","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1124\/jpet.114.213819","volume":"350","author":"K Maeda","year":"2014","unstructured":"Maeda K, Lerdrup L, Sugino H, Akazawa H, Amada N, McQuade RD, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):605\u201314.","journal-title":"J Pharmacol Exp Ther"},{"key":"579_CR28","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/ijcp.12714","volume":"69","author":"L Citrome","year":"2015","unstructured":"Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic. What is the number needed to treat, number needed to harm and likelihood to be helped or harmed. Int J Clin Pract. 2015;69:978\u201397.","journal-title":"Int J Clin Pract"},{"key":"579_CR29","doi-asserted-by":"crossref","unstructured":"Brexpiprazole for schizophrenia. Aust Prescr. 40(5):197\u20138.","DOI":"10.18773\/austprescr.2017.064"},{"issue":"1","key":"579_CR30","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1124\/jpet.109.160432","volume":"333","author":"B Kiss","year":"2010","unstructured":"Kiss B, Horvath A, Nemethy Z, Schmidt E, Laszlovszky I, Bugovics G, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333(1):328\u201340.","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"579_CR31","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1016\/j.bmcl.2012.03.104","volume":"22","author":"\u00c9 \u00c1gai-Csongor","year":"2012","unstructured":"\u00c1gai-Csongor \u00c9, Dom\u00e1ny G, N\u00f3gr\u00e1di K, Galambos J, V\u00e1g\u00f3 I, Keser GM, et al. Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D 3\/D 2 receptors. Bioorganic Med Chem Lett. 2012;22(10):3437\u201340.","journal-title":"Bioorganic Med Chem Lett"},{"issue":"1","key":"579_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/bdi.12238","volume":"17","author":"S Durgam","year":"2015","unstructured":"Durgam S, Starace A, Li D, Migliore R, Ruth A, N\u00e9meth G, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015;17(1):63\u201375.","journal-title":"Bipolar Disord"},{"issue":"3","key":"579_CR33","doi-asserted-by":"publisher","first-page":"284","DOI":"10.4088\/JCP.14m09081","volume":"76","author":"JR Calabrese","year":"2015","unstructured":"Calabrese JR, Keck PE, Starace A, Lu K, Ruth A, Laszlovszky I, et al. Efficacy and safety of low- and high-dose Cariprazine in acute and mixed mania associated with bipolar i disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2015;76(3):284\u201392.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"579_CR34","first-page":"34","volume":"15","author":"G Mattingly","year":"2016","unstructured":"Mattingly G, Anderson R. Cariprazine for schizophrenia and bipolar I disorder. Curr Psychiatry. 2016;15(2):34\u20139.","journal-title":"Curr Psychiatry"},{"key":"579_CR35","first-page":"1657","volume":"11","author":"F-M Werner","year":"2015","unstructured":"Werner F-M, Cove\u00f1as R. New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine. Ther Clin Risk Manag. 2015;11:1657\u201361.","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"579_CR36","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1176\/appi.ajp.2013.13070984","volume":"171","author":"A Loebel","year":"2014","unstructured":"Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, et al. Lurasidone monotherapy in the treatment of bipolar i depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160\u20138.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"579_CR37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1124\/jpet.110.167346","volume":"334","author":"T Ishibashi","year":"2010","unstructured":"Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334(1):171\u201381.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"579_CR38","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1515\/dmdi-2014-0005","volume":"29","author":"Y-Y Chiu","year":"2014","unstructured":"Chiu Y-Y, Ereshefsky L, Preskorn SH, Poola N, Loebel A. Lurasidone drug-drug interaction studies: a comprehensive review. Drug Metabol Drug Interact. 2014;29(3):191\u2013202.","journal-title":"Drug Metabol Drug Interact"},{"key":"579_CR39","unstructured":"Latuda. Latuda (Lurasidone): Highlights of prescribing information."},{"issue":"2012","key":"579_CR40","first-page":"1","volume":"2016","author":"M Sajatovic","year":"2013","unstructured":"Sajatovic M, Forester BP, Tsai J, Kroger H, Pikalov A, Cucchiaro J, et al. Efficacy of lurasidone in adults aged 55 years and older with bipolar depression: post hoc analysis of 2 double-blind, placebo-controlled studies. J Clin Psychiatry. 2013;2016(2012):1\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"579_CR41","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jagp.2017.08.013","volume":"26","author":"BP Forester","year":"2018","unstructured":"Forester BP, Sajatovic M, Tsai J, Pikalov A, Cucchiaro J, Loebel A. Safety and effectiveness of long-term treatment with Lurasidone in older adults with bipolar depression: post-hoc analysis of a 6-month, open-label study. Am J Geriatr Psychiatry. 2018;26(2):150\u20139.","journal-title":"Am J Geriatr Psychiatry"},{"key":"579_CR42","unstructured":"FDA, Center for Drug Evaluation and Research. Granisetron: highlights of prescribing information."},{"issue":"3","key":"579_CR43","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.clinthera.2011.03.006","volume":"33","author":"BL Crabtree","year":"2011","unstructured":"Crabtree BL, Montgomery J. Iloperidone for the management of adults with schizophrenia. Clin Ther. 2011;33(3):330\u201345.","journal-title":"Clin Ther"},{"issue":"6","key":"579_CR44","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/WNF.0b013e3182aa38c4","volume":"36","author":"S-M Wang","year":"2013","unstructured":"Wang S-M, Han C, Lee S-J, Patkar AA, Masand PS, Pae C-U. Asenapine, blonanserin, iloperidone, lurasidone, and sertindole. Clin Neuropharmacol. 2013;36(6):223\u201338.","journal-title":"Clin Neuropharmacol"},{"issue":"10","key":"579_CR45","first-page":"5","volume":"6060","author":"E Richelson","year":"1999","unstructured":"Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry. 1999;6060(10):5\u201314.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"579_CR46","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S0893-133X(01)00285-8","volume":"25","author":"HO Kalkman","year":"2001","unstructured":"Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine\/serotonin\/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology. 2001;25(6):904\u201314.","journal-title":"Neuropsychopharmacology"},{"key":"579_CR47","unstructured":"Sedek G, Wolfgang C. Iloperidone is well tolerated by subjects with renal or hepatic impairment in single-dose clinical pharmacokinetic studies. In: American Psychiatric Association Annual Meeting; 19\u201324 May 2007: San Diego, CA."},{"issue":"Suppl. 1","key":"579_CR48","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1097\/JCP.0b013e3181692787","volume":"28","author":"SG Potkin","year":"2008","unstructured":"Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of Iloperidone in the Treatment of Schizophrenia. J Clin Psychopharmacol. 2008;28(Suppl. 1):S4\u201311.","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl. 1","key":"579_CR49","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1097\/JCP.0b013e3181694f5a","volume":"28","author":"PJ Weiden","year":"2008","unstructured":"Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone. J Clin Psychopharmacol. 2008;28(Suppl. 1):S12\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"579_CR50","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1586\/ecp.12.70","volume":"6","author":"WV Bobo","year":"2013","unstructured":"Bobo WV. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013;6(1):61\u201391.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"579_CR51","first-page":"146","volume-title":"Stahl\u2019s Essential psychopharmacology: neuroscientific basis and practical applications. Mens Sana monographs","author":"C Andrade","year":"2010","unstructured":"Andrade C. Stahl\u2019s Essential psychopharmacology: neuroscientific basis and practical applications. Mens Sana monographs, vol. 8. 4th ed. Barcelona, Cambridge: University Press; 2010. p. 146.","edition":"4"},{"issue":"1","key":"579_CR52","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/acps.12262","volume":"130","author":"M Pratts","year":"2014","unstructured":"Pratts M, Citrome L, Grant W, Leso L, Opler LA. A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatr Scand. 2014;130(1):61\u20138.","journal-title":"Acta Psychiatr Scand"},{"key":"579_CR53","first-page":"1","volume-title":"Product monograph: asenapine","author":"Janssen","year":"2003","unstructured":"Janssen. Product monograph: asenapine. New York: Janssen; 2003. p. 1\u201352."},{"issue":"2\u20133","key":"579_CR54","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.schres.2010.02.417","volume":"117","author":"SL Dubovsky","year":"2010","unstructured":"Dubovsky SL, Frobose C, Phiri P, Panagides J. Short-term tolerability, safety, and pharmacokinetic profile of asenapine in older patients with psychosis. Schizophr Res. 2010;117(2\u20133):263\u20134.","journal-title":"Schizophr Res"},{"issue":"2","key":"579_CR55","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40268-015-0092-x","volume":"15","author":"M Corena-McLeod","year":"2015","unstructured":"Corena-McLeod M. Comparative pharmacology of risperidone and paliperidone. Drugs R D. 2015;15(2):163\u201374.","journal-title":"Drugs R D"},{"issue":"6","key":"579_CR56","first-page":"869","volume":"3","author":"PG Janicak","year":"2007","unstructured":"Janicak PG, Winans E. Paliperidone ER: a review of the clinical trial data. Neuropsychiatr Dis Treat. 2007;3(6):869\u201397.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"579_CR57","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1176\/appi.ajp.162.5.1010","volume":"162","author":"R Knegtering","year":"2005","unstructured":"Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, Van Den Bosch RJ. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry. 2005;162(5):1010\u20132.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"579_CR58","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3109\/10398561003686763","volume":"18","author":"M Skopek","year":"2010","unstructured":"Skopek M, Manoj P. Hyperprolactinaemia during treatment with paliperidone. Australas Psychiatry. 2010;18(3):261\u20133.","journal-title":"Australas Psychiatry"},{"issue":"4","key":"579_CR59","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1124\/dmd.107.018275","volume":"36","author":"M Vermeir","year":"2008","unstructured":"Vermeir M, Naessens I, Remmerie B, Mannens G, Hendrickx J, Sterkens P, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos. 2008;36(4):769\u201379.","journal-title":"Drug Metab Dispos"},{"issue":"1\u20133","key":"579_CR60","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jad.2010.09.011","volume":"129","author":"J Berwaerts","year":"2011","unstructured":"Berwaerts J, Lane R, Nuamah IF, Lim P, Remmerie B, Hough DW. Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. J Affect Disord. 2011;129(1\u20133):252\u201360.","journal-title":"J Affect Disord"},{"issue":"3","key":"579_CR61","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jad.2012.01.047","volume":"138","author":"J Berwaerts","year":"2012","unstructured":"Berwaerts J, Melkote R, Nuamah I, Lim P. A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar i disorder after an acute manic or mixed episode. J Affect Disord. 2012;138(3):247\u201358.","journal-title":"J Affect Disord"},{"key":"579_CR62","unstructured":"FDA Label. Aripiprazole abilify FDA-label. Interactions. 1998;50:1\u201325. \n                    http:\/\/pi.lilly.com\/us\/zyprexa-pi.pdf\n                    \n                  ."},{"issue":"10","key":"579_CR63","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s40265-014-0231-7","volume":"74","author":"M Shirley","year":"2014","unstructured":"Shirley M, Perry CM. Aripiprazole (ABILIFY MAINTENA\u00ae): a review of its use as maintenance treatment for adult patients with schizophrenia. Drugs. 2014;74(10):1097\u2013110.","journal-title":"Drugs"},{"key":"579_CR64","unstructured":"H. Lundbeck A\/S (Lundbeck) and Otsuka Pharmaceutical Co. L. Abilify Maintena\u00ae (aripiprazole) for extended-release injectable suspension approved by the US FDA for maintenance monotherapy treatment of bipolar I disorder. Lundbeck; 2017."},{"issue":"9896","key":"579_CR65","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, \u00d6rey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951\u201362.","journal-title":"Lancet"},{"issue":"1","key":"579_CR66","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4088\/JCP.v69n0106","volume":"69","author":"M Sajatovic","year":"2008","unstructured":"Sajatovic M, Coconcea N, Ignacio RV, Blow FC, Hays RW, Cassidy KA, et al. Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial. J Clin Psychiatry. 2008;69(1):41\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"10011","key":"579_CR67","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(15)00308-6","volume":"386","author":"EJ Lenze","year":"2015","unstructured":"Lenze EJ, Mulsant BH, Blumberger DM, Karp JF, Newcomer JW, Anderson SJ, et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(10011):2404\u201312.","journal-title":"Lancet"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-018-0579-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-0579-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-0579-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T09:09:06Z","timestamp":1567760946000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-018-0579-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,6]]},"references-count":67,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["579"],"URL":"https:\/\/doi.org\/10.1007\/s40266-018-0579-6","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,6]]},"assertion":[{"value":"6 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Akshya Vasudev, Sumit Chaudhari, Rickinder Sethi, Rachel Fu, Rachel M. Sandieson and Brent P. Forester have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}